Q1 EPS Estimate for Bausch Health Cos Lowered by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Equities research analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Bausch Health Cos in a research note issued on Wednesday, March 11th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.81 per share for the quarter, down from their previous estimate of $0.82. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q2 2026 earnings at $0.94 EPS, Q3 2026 earnings at $1.06 EPS, Q4 2026 earnings at $1.10 EPS, FY2026 earnings at $3.92 EPS, Q1 2027 earnings at $0.82 EPS, Q3 2027 earnings at $1.12 EPS, Q4 2027 earnings at $0.97 EPS and FY2027 earnings at $3.79 EPS.

BHC has been the topic of a number of other reports. Weiss Ratings lowered shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a report on Thursday, February 19th. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Barclays decreased their price objective on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, February 25th. Wall Street Zen cut Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Finally, Truist Financial raised their price target on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bausch Health Cos currently has a consensus rating of “Reduce” and an average price target of $8.33.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $5.42 on Thursday. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.47. Bausch Health Cos has a 52 week low of $4.25 and a 52 week high of $8.69. The company’s 50 day moving average price is $6.28 and its two-hundred day moving average price is $6.56. The company has a market capitalization of $2.02 billion, a P/E ratio of 12.91 and a beta of 0.37.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 EPS for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The business had revenue of $2.78 billion for the quarter, compared to analyst estimates of $2.71 billion.

Hedge Funds Weigh In On Bausch Health Cos

A number of institutional investors have recently added to or reduced their stakes in BHC. Paulson & CO. Inc. raised its position in Bausch Health Cos by 3.5% during the fourth quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock worth $509,128,000 after acquiring an additional 2,500,000 shares in the last quarter. Goldentree Asset Management LP grew its position in shares of Bausch Health Cos by 1.7% in the 3rd quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock valued at $224,409,000 after acquiring an additional 578,542 shares during the period. Vanguard Group Inc. increased its stake in shares of Bausch Health Cos by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock worth $78,808,000 after purchasing an additional 470,968 shares during the last quarter. Maple Rock Capital Partners Inc. raised its holdings in shares of Bausch Health Cos by 14.9% in the 2nd quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock valued at $52,005,000 after purchasing an additional 1,010,987 shares during the period. Finally, SG Americas Securities LLC raised its holdings in shares of Bausch Health Cos by 114.4% in the 2nd quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock valued at $40,979,000 after purchasing an additional 3,282,684 shares during the period. 78.65% of the stock is currently owned by institutional investors and hedge funds.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.